A photo-decomposable compound, a photoresist composition, and a method of manufacturing an IC device, the compound generating acid upon exposure and acts as a quenching base that neutralizes acid in an unexposed state and being represented by Formula 1:

##STR00001## wherein, in Formula 1, R.sup.a is a C5 to C40 substituted or unsubstituted cyclic hydrocarbon group including at least one nitrogen atom, Y.sup.a is a C1 to C20 divalent linear or cyclic hydrocarbon group, n is an integer of 1 to 5, and A.sup.+ is a counter ion.

Lipid nanoparticle compositions for delivery of nucleic acids are described. The lipid nanoparticle may contain a conformationally constrained ionizable lipid as part of the composition. These compositions may allow for delivery of cargo without the need for a targeting ligand.

Disclosed herein are compounds having a structure of formula (I), compositions and methods useful for the treatment of a disease or infection, such as a viral infection (e.g., Ebola), cancer and obesity:

##STR00001##

wherein A is N or CR.sup.8; Z is

##STR00002## E is selected from optionally substituted alkyl, cycloalkyl, arylalkyl, cycloalkylalkyl, amino, alkoxy, cycloalkyloxy, and cycloalkylamino; R.sup.1 is selected from optionally substituted aryl and heteroaryl, R.sup.2 and R.sup.3 are independently selected from H, deutero, optionally substituted alkyl, haloalkyl, or R.sup.2 and R.sup.3, together with the carbon to which they are bound, combine to form a carbonyl; and R.sup.8 is selected from H, deutero, halo, hydroxyl, cyano, amino, alkyl, alkoxy, carboxy, alkoxycarbonyl, and aminocarbonyl, provided that E is not

##STR00003##

Disclosed herein are compounds having a structure of formula (I), compositions and methods useful for the treatment of a disease or infection, such as a viral infection (e.g., Ebola), cancer and obesity:

##STR00001##

wherein A is N or CR.sup.8; Z is

##STR00002## E is selected from optionally substituted alkyl, cycloalkyl, arylalkyl, cycloalkylalkyl, amino, alkoxy, cycloalkyloxy, and cycloalkylamino; R.sup.1 is selected from optionally substituted aryl and heteroaryl, R.sup.2 and R.sup.3 are independently selected from H, deutero, optionally substituted alkyl, haloalkyl, or R.sup.2 and R.sup.3, together with the carbon to which they are bound, combine to form a carbonyl; and R.sup.8 is selected from H, deutero, halo, hydroxyl, cyano, amino, alkyl, alkoxy, carboxy, alkoxycarbonyl, and aminocarbonyl, provided that E is not

##STR00003##

Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (I) as follows: ##STR00001## wherein R.sup.1, R.sup.2, R.sup.3, A, W, L, R.sub.a, and G are defined herein:
and by Formula (II) as follows: ##STR00002##
wherein R.sup.1B, W.sub.B, L.sub.B, , and G.sub.B are defined herein.

A pyridone compound represented by Formula (1): ##STR00001##
wherein R1, R2, X, Y and Z are defined. The pyridone compound can control plant diseases.

A pyridone compound represented by Formula (1): ##STR00001##
wherein R1, R2, X, Y and Z are defined. The pyridone compound can control plant diseases.

Substituted pyrimidine and pyridines as NR2B receptor ligands, for example ##STR00001##
Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.

Substituted pyrimidine and pyridines as NR2B receptor ligands, for example ##STR00001##
Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.

Described herein, inter alia, are compositions of PCNA modulators and methods for treating or preventing cancer.